



CARDIONEPHROLOGY 2019



Rome, March 12/14, 2019

Venue: Ergife Palace Hotel
Largo Lorenzo Mossa

Cover:

Rome, Castel Sant'Angelo or Hadrian's Tomb.

ENDORSEMENT



*ERA-EDTA's endorsement is for the promotion of education in general,
therefore the specific content of the event is the responsibility of the organiser*

ENDORSEMENT REQUESTED

High Patronage of the President of the Republic

International Society of Nephrology

Italian Society of Nephrology

Italian Society of Artificial Nutrition

Italian Society of Cardiovascular Ultrasound System

SCIENTIFIC ADVISORS

Luca Di Lullo, Antonio Bellasi

PRESIDENTS

Claudio Ronco, Alberto Santoboni, Antonio De Pascalis

HONORARY PRESIDENT

Peter Mc Cullough

ORGANIZING SECRETARIAT



Fenicia Events & Communication

info@fenicia-events.eu

WELCOME LETTER

Cardiovascular and renal disease are closely linked through different mechanisms such as chronic inflammation, dyslipidemia, calcium-phosphorus metabolism abnormalities, or comorbid conditions such as arterial hypertension, coronary artery disease and diabetes which may affect the heart and the kidneys at the same or in different times. At the same time, different hereditary (such as Polycystic kidney disease) and/or rare (such as Fabry's disease) diseases also may impair simultaneously renal and cardiovascular functions.

The fourth edition of the CardioNephrology meeting will review comorbidities and metabolic abnormalities from the cardiorenal syndrome to the metabolic consequences of chronic kidney and heart disease that occur as the glomerular filtration rate decreases and link kidney and cardiovascular diseases.

The key features of the CardioNephrology 2019 are represented by the scientific sessions dedicated to the close interactions between heart, kidney and lung together with nutritional aspects in cardio – renal patients. Heart failure will be discussed both in acute and chronic kidney disease patients. Lectures dedicated to imaging will underscore potentials and limits of available diagnostic tools. Young cardioneurologists will be also specifically involved in vasculitis – dedicated as far as in poster session.

CardioNephrology 2019 will also focus on specific educational courses dedicated to critical appraisal, interventional nephrology, electrocardiography and blood gas analysis.

The meeting is arranged on several scientific sessions (some of them joined with other eminent scientific societies) and selected plenary lectures with eminent national and international speakers.

Finally, Meeting will close with World Kidney Day 2019 with several activities directly linked to this special issue.

Enjoy CardioNephrology 2019 with us

Luca Di Lullo, Antonio Bellasi, Claudio Ronco, Antonio De Pascalis, Alberto Santoboni, Peter Mc Cullough



DAY ONE - Tuesday March 12th 2019

LEPTIS MAGNA 2-4 ROOM

Chairmen: *A. De Pascalis* (Lecce), *A. Santoboni* (Colleferro)

- 9.00** Coronary angiography e and contrast-induced nephropathy risk
G.P. Talarico (Rome)
- 9.15** Folic acid and cardiovascular prevention
G. Cianciolo (Bologna)
- 9.30** Sleep disturbances in CKD diabetic patients
TBA
- 9.45** Fluid assessment in heart failure patients with chronic kidney disease: the role of telehealth an telemedicine
A. Martino (Rome)
- 10.00** Cardiorenal involvement in adrenocortical failure
A. Falorni (Perugia)
- 10.15** Left atrial appendage occlusion in end-stage renal disease patients: an alternative to oral anticoagulant approach
G. Patti (Rome)
- 10.35** Pain therapy in cardio-renal patients
TBA
- 10.50** Chronic inflammation in cardiorenal patients: hepcidin-C-reactive protein and lactoferrin
L. Di Lullo (Colleferro)
- 11.05** Hypertonic solutions for peritoneal dialysis patients
V. Barbera (Colleferro)

- 11.25** Cardiorenal anemia management: the role of biosimilar erythropoiesis-stimulating agents (ESA)
TBA
- 11.45** CKD, Cardiorenal syndrome and dyslipidemia: an unsolved puzzle
P. Terrosu (Sassari)
- 12.05** Cardiovascular interventional proceedings in end-stage renal disease patients
A. Granatelli (Tivoli)
- 12.20** Bioequivalence and bioavailability in cardiorenal patients' treatment
TBA
- 12.40** Cardio and renal update on new treatment's perspectives in Fabry's disease
F. Pieruzzi (Monza)

LEPTIS MAGNA 1 ROOM

No Translation Tool available for this Session

- 9.00** ECG Educational Course
Discussant: *A. De Pascalis (Lecce), R. Rivera (Desio)*

TARRAGONA ROOM

No Translation Tool available for this Session

- 9.00** EGA Educational Course
Discussant: *M.T. Sciarrone Alibrandi (Monza), U. Tulli (Tivoli)*

CESAREA ROOM

No Translation Tool available for this Session

- 9.00** Interventional Nephrology Educational Course
Discussant: *A. Granata (Agrigento), N. Pirozzi (Rome), M. Tozzi (Varese)*

THUGGA ROOM

No Translation Tool available for this Session

- 9.00** Critical appraisal in cardioneurology
C. Torino, G. Tripepi (Reggio Calabria)

13.00 *Light Lunch*

LEPTIS MAGNA 2-4 ROOM

14.00 OPENING PLENARY LECTURE

The link between chronic inflammation and cardiovascular disease in CKD

P. Raggi (Edmonton - Canada)

Introducing: *C. Ronco* (Vicenza)

LEPTIS MAGNA 2-4 ROOM

I SESSION

CARDIOVASCULAR RISK FACTORS IN CHRONIC KIDNEY DISEASE PATIENTS (CKD): NEW THERAPEUTIC APPROACHES

Chairmen: *A. Granatelli* (Tivoli), *P. Menè* (Rome)

- 14.30** Cardiorenal anemia syndrome: what's new?
F. Locatelli (Lecco)

- 15.00** Anti PCSK9 antibodies in dyslipidemic patients with CKD: from clinical trials to real world evidences
A. Zambon (Padova)

- 15.30** Xanthine oxidase inhibitors and novel uricosuric agents for uric acid-related cardioneuropathy treatment
L. Di Lullo (Colleferro), *L. Gesualdo* (Bari)

16.10 Chronic inflammation and cardiovascular risk: new treatment's perspectives
TBA

16.30 Obesity, cardiovascular disease and CKD
F. Muratori (Como)

LEPTIS MAGNA 1

I SESSION

DIRECT ORAL ANTICOAGULANTS (DOACs) AND CHRONIC KIDNEY DISEASE: A THREE-STEPS FLOW-CHART

Chairmen: *S. Caramiello* (Rome), *A. Mugnolo* (Legnago)

FIRST STEP: Management

14.30 Fragile patients and anticoagulant therapy between guidelines and real life
L. Di Lullo (Colleferro)

14.45 Two dosages for the same drug: two sides of the same coin?
R. Pola (Rome)

15.00 Emergencies management in DOACs treated patients
D. Toni (Rome)

SECOND STEP: Appropriateness

15.15 DOACs prescriptive appropriateness in atrial fibrillation patients with CKD
L. De Luca (Tivoli)

15.30 DOACs therapy according to patients phenotypes: a matter of safety? Anything else?
M. Ciavolella (Frascati)

- 15.45** DOACs and advanced CKD stages
L. Di Lullo (Colleferro)

THIRD STEP: Complexity

- 16.00** Direct oral anticoagulant therapy in patients with active cancer: between atrial fibrillation and deep venous thromboembolism
I. Bisceglia (Rome)
- 16.15** Direct oral anticoagulant therapy once daily treatment and thromboembolic prophylaxis in CKD patients
S. Radicchia (Perugia)
- 16.30** Efficacy and safety profile of direct oral anticoagulant therapy in old and fragile patients
M. Ciaburri (Rome)

TARRAGONA ROOM

I SESSION

CARDIOVASCULAR FEATURES OF KIDNEY TRANSPLANT PATIENTS

Chairmen: *G. Grandaliano* (Foggia), *G. Otranto* (Colleferro)

- 14.30** Which cardiologic evaluation for kidney transplantation patients' waiting list?
L. Potena (Bologna)
- 15.00** Cardiovascular ageing in transplant patients: immune response and immunosuppressive treatment roles
G. Stallone (Foggia)
- 15.30** Cardiovascular involvement in transplant patients: how to manage?
E. Paoletti (Genoa)

16.00 Optimal timing of HCV-related hepatic disease treatment in kidney transplant recipients
G. Taliani (Rome)

16.30 Discussion

16.45 *Coffee Break*

LEPTIS MAGNA 2-4 ROOM

II SESSION INTEGRATED MEDICINE AND CARDIONEPHROLOGY

Chairmen: *S. Castellino* (Taormina), *A. Gorini* (Rome)

17.00 Immune system involvement in cardiorenal diseases
M. Del Prete (Milan)

17.15 Herbal extracts as metabolic interferences: potential clinical uses
G. Occhionero (Isernia)

17.30 Biophysical integrated approach on cardionephrology:
an emerging clinical perspective
A. Foletti (Lugano - Switzerland)

17.45 Stem cells as treatment option in cardiac diseases: available results
C. Castellitto (Bologna)

18.00 Discussion

LEPTIS MAGNA 1 ROOM

II SESSION

LUNG, KIDNEY AND HEART AXIS

Chairmen: *L. Di Lullo* (Colleferro), *C. Ronco* (Vicenza)

- 17.00** Kidney, heart and lung: three sides of the same picture
Z. Ricci (Rome)
- 17.15** Chronic obstructive lung disease, right heart failure and kidney disease
S. Di Simone (Colleferro)
- 17.30** New anti-cholinergic agents for chronic obstructive lung disease: safety profile in cardiorenal patients
TBA
- 17.45** Primary and secondary pulmonary hypertension in CKD
M.P. Cicini (Rome)
- 18.00** Discussion

TARRAGONA ROOM

II SESSION

17.00 QUESTIONS' CLINIC WITH THE EXPERTS: CARDIORENAL SYNDROME

Chairmen: *J. Kellum* (Philadelphia - USA), *C. Ronco* (Vicenza)

LEPTIS MAGNA 2-4 ROOM

III SESSION

CLINICAL HISTORY OF CARDIO-RENAL SYNDROME

Chairmen: *A. De Pascalis* (Lecce), *R. Rivera* (Desio)

- 18.15** Post-AKI kidney functional recovery
J. Kellum (Pittsburgh - USA)
- 18.30** Progression of kidney disease: from AKI to CKD
G. Grandaliano (Foggia)
- 18.45** Sepsis-related kidney damage
V. Cantaluppi (Novara)
- 19.00** The role of renal functional reserve
C. Ronco (Vicenza)
- 19.15** Discussion

LEPTIS MAGNA 1 ROOM

III SESSION

CARDIAC ARRHYTHMIAS AND CHRONIC KIDNEY DISEASE

Chairmen: *M. Mennuni* (Colleferro), *M. Rebecchi* (Rome)

- 18.15** Pathophysiology of arrhythmias in CKD patients
D. Grieco (Rome)
- 18.30** Heart rhythm impairment: the silent killer
S. Mennuni (Rome)
- 18.45** Atrial fibrillation: prevention and treatment in renal replacement treatment's patients
A. Politano (Rome)

19.00 Atrial fibrillation: anticoagulation and hemodialysis
M. Sgueglia (Rome)

19.15 Discussion

TARRAGONA ROOM

III SESSION FUNCTIONAL FOODS AND NUTRACEUTICS IN CARDIORENAL PATIENTS

Chairmen: *V. Barbera* (Colleferro), *F. Santoboni* (Rome)

18.15 Pharmacological interactions and the treatment of
dyslipidemia: how and when to treat
R. Volpe (Rome)

18.30 Nutraceuticals and dyslipidemia management in cardiorenal patients
C. Morozzi (Rome)

18.45 Hypercholesterolemia targets in high risk cardiorenal patients:
beyond the statins
V. Barbera (Colleferro)

19.00 Iron deficiency and anemia in CKD patients: new therapeutic
approaches
N. Marchitto (Terracina)

19.15 Prevention and treatment of nephrolithiasis
TBA

LEPTIS MAGNA 2-4 ROOM

19.30 OPENING CERIMONY

AUTHORITIES' GREETINGS

20.00 Closing



DAY TWO – Wednesday March 13th 2019

LEPTIS MAGNA 2-4 ROOM

IV SESSION

ARTERIAL HYPERTENSION

Chairmen: *A. Balducci* (Rome), *G. Reboldi* (Perugia)

8.30 ESC/ESH and ACC guidelines: what's new? What's different?
F. Mallamaci (Reggio Calabria)

8.45 Anti-hypertensive treatment and nephro-protection?
Which target to achieve?
R. Pontremoli (Genoa)

9.00 Arterial hypertension in hemodialysis patients: how to treat?
And which target values to achieve?
L. De Nicola (Naples)

9.15 Resistant hypertension and cardiorenal risk: bad compliance or poor efficacy?
F. Viazzi (Genoa)

9.30 Potential new targets for antihypertensive therapy
K. Narkiewicz (Gdansk - Poland)

9.45 Discussion

10.00 PLENARY LECTURE

Management of chronic ischemic disease in CKD patients

G. Ferraiuolo (Rome)

Introducing: *A. Santoboni* (Colleferro)

LEPTIS MAGNA 1 ROOM

IV SESSION

FABRY'S DISEASE

Chairmen: *S. Feriozzi* (Viterbo), *F. Graziani* (Rome)

8.30 Natural history of Fabry's disease

F. Floccari (Civitavecchia)

8.45 Fabry's disease: from glomerular hyperfiltration to overt CKD

A. Pisani (Naples)

9.00 Fabry's disease: from arterial hypertension to hypertrophic cardiomyopathy

C. Autore (Rome)

9.15 Neurologic involvement in Fabry's disease

G. Silvestri (Rome)

9.30 Fabry's disease progression and biomarkers

R. Mignani (Rimini)

9.45 Discussion

10.00 **PLENARY LECTURE**

Cardiorenal Amyloidosis

C. Rapezzi (Bologna)

Introducing: *C. Ronco* (Vicenza)

TARRAGONA ROOM

IV SESSION

JOINT SESSION CARDIONEPHROLOGY STUDY GROUP - ITALIAN SOCIETY OF ARTIFICIAL NUTRITION

NUTRITIONAL AND METABOLIC FEATURES IN CARDIORENAL PATIENTS

Chairmen: *L. Gianotti* (Monza), *G. Iapichino* (Milan)

8.30 Nutritional status evaluation in kidney disease patients
E. Giaquinto (Cesena)

8.50 Nutritional therapy in CKD patients
A. Cupisti (Pisa)

9.10 Kidney-Intestinal microbiota Axis
S. Riso (Vercelli)

9.30 Artificial nutrition in AKI patients
M. Zanello (Bologna)

9.50 Malnutrition and cardiorenal syndrome
D. Radrizzani (Legnano)

10.10 Obesity paradox and acute kidney failure
M. Zanetti (Trieste)

EXHIBIT HALL

10.30 Coffee Break with the Expert

LEPTIS MAGNA 2-4 ROOM

V SESSION

ACUTE KIDNEY INJURY

Chairmen: *P. Raggi* (Edmonton - Canada), *C. Ronco* (Vicenza)

- 11.30** AKI: epidemiology and clinical features
C. Ronco (Vicenza)
- 11.45** AKI and heart failure
P. Mc Cullough (Dallas, Texas - USA)
- 12.00** Cytokines removal and cardiac surgery
V. Cantaluppi (Novara)
- 12.15** AKI and sepsis
J. Kellum (Philadelphia - USA)
- 12.30** Endotoxins and type - 1 cardorenal syndrome
M.G. Virzi (Vicenza)
- 12.45** Renal replacement treatments in AKI patients
C. Ronco (Vicenza)
- 13.00** Discussion

LEPTIS MAGNA 1 ROOM

V SESSION

HEART FAILURE MANAGEMENT IN CARDIORENAL PATIENTS

Chairmen: *E. Ferramosca* (Lecce), *A. Santoro* (Bologna)

- 11.30** Diuretics, heart failure-related systemic congestion and Karl Popper's turkey
G. Cice (Naples)

- 11.45** Neprilisine inhibition in heart failure
C. Parisi (Rome)
- 12.00** Guanylate cyclase stimulators and heart failure
A. Fucili (Ferrara)
- 12.15** Therapeutic strategies for chronic hyperkalemia in heart failure patients
A. Bellasi (Bergamo)
- 12.30** Intra and extracorporeal fluids balance in heart failure
P. Mc Cullough (Dallas, Texas - USA)
- 12.45** Extracorporeal's fluids removal in patients affected by cardiorenal syndrome
V. Panichi (Versilia)
- 13.00** Apheresis and cardio-renal syndrome
A. Santoro (Bologna)
- 13.15** Discussion

TARRAGONA ROOM

V SESSION

ACUTE CORONARY SYNDROME AND CHRONIC RENAL FAILURE

Chairmen: *G. Patti* (Rome), *A. Rubboli* (Bologna)

- 11.30** Which does eGFR equation better predict outcome in patients with acute coronary syndrome?
F. Floccari (Civitavecchia)
- 11.45** Patients with acute coronary syndrome and chronic renal failure: contemporary trends on early treatment strategies
M. Tubaro (Rome)

- 12.00** Impact of chronic renal failure at early and one-year follow-up after acute coronary syndrome:
a) The bleeding risk outweighs the ischemic risk!
V. Pengo (Padua)
b) The ischemic risk outweighs the bleeding risk!
P. Calabrò (Naples)
- 12.30** Acute coronary syndrome and chronic renal failure: which data from real-world registries?
a) ISAC Registry
R. Bugiardini (Bologna)
b) START ANTIPLATELET Registry
R. Marcucci (Florence)
- 13.00** Long-term antithrombotic therapy in patients with chronic renal failure and previous acute coronary syndrome: new evidence
G. Di Pasquale (Bologna)
- 13.15** Discussion

LEPTIS MAGNA 2-4 ROOM

LUNCHEON SYMPOSIUM

PERITONEAL DIALYSIS IN CARDIORENAL PATIENTS

Chairmen: *C. Crepaldi* (Vicenza), *A.R. Rocca* (Rome)

- 13.30** Clinical studies of PD in cardiorenal syndrome and heart failure
A. Kazory (Gainesville - USA)
- 13.45** Fluids' balance in peritoneal dialysis
O. Heimbürger (Stockholm - Sweden)
- 14.00** The pathophysiology of the cardiorenal syndrome and potential use of peritoneal ultrafiltration
J. Bargman (Toronto - Canada)

14.15 PUF and CHF: the italian experience of a multidisciplinary approach
G.M. Iadarola (Turin)

14.30 Discussion

LEPTIS MAGNA 1 ROOM

LUNCHEON SYMPOSIUM HEMODIALYSIS TREATMENTS AND CARDIORENAL PATIENTS

Chairmen: *M. Morosetti* (Rome), *P. Trambaiolo* (Rome)

13.30 Immunoabsorption in heart transplant's patients
C. Maiello (Naples)

13.50 Electrolytes'balance in Continuous Renal Replacement Therapy with citrate
S. Morabito (Rome)

14.10 Immunomodulation in septic patients
G. Paternoster (Potenza)

14.30 Discussion

TARRAGONA ROOM

LUNCHEON SYMPOSIUM HEART FAILURE: POTENTIAL APPROACHES FROM ACUTE TO CHRONIC SETTINGS

Chairman: *E. Galli* (Treviglio), *V. La Milia* (Milan)

13.30 Continuous ultrafiltration and extracorporea devices: techniques and outcomes
V. Cantaluppi (Novara)

- 13.50** Wearable device-based PUF (Peritoneal Ultrafiltration)
TBA
- 14.10** Frequent hemodialysis in heart failure patients
TBA
- 14.30** Discussion

CESAREA ROOM

- 13.30 LUNCHEON SYMPOSIUM**
TBA

LEPTIS MAGNA 2-4 ROOM

VI SESSION

RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS (RAASi) ENABLING THERAPIES AND CHRONIC HYPERKALEMIA MANAGEMENT

Chairmen: *L. De Nicola* (Naples), *E. Paoletti* (Genoa)

- 15.00** Epidemiology and diagnosis of chronic hyperkalemia
L. De Nicola (Naples)
- 15.15** Chronic hyperkalemia risk factors
E. Paoletti (Genoa)
- 15.30** RAAS inhibition and hyperkalemia
G. Pajes (Albano Laziale)
- 15.45** Therapeutic strategies for chronic hyperkalemia:
a) Dietetic interventions
A. Cupisti (Pisa)
b) Pharmacological options
S. Bianchi (Livorno)
- 16.15** Discussion

LEPTIS MAGNA 1 ROOM

VI SESSION

AUTOSOMIC DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) AND CARDIO-RENAL INVOLVEMENT

Chairmen: *M. Galliani* (Rome), *P. Peverini* (Rieti)

15.00 ADPKD: an up to date

L. Trepiccione (Naples)

15.15 Disease's progression models:

a) ERA-EDTA approach

R. Torra (Barcelona - Spain)

b) Italian approach

F. Scolari (Brescia)

15.45 Imaging diagnosis in ADPKD patients

A. Granata (Agrigento)

16.00 Therapeutic management of ADPKD patients: real world data and future perspectives

R. Magistroni (Modena)

16.15 Patient's interview

F. Floccari (Civitavecchia)

TARRAGONA ROOM

VI SESSION

QUESTIONS' CLINIC: CLINICAL CARDIONEPHROLOGY

Chairmen: *A. Bellasi* (Bergamo), *R. Rivera* (Desio)

EXHIBIT HALL

16.30 Coffee Break with the Expert

LEPTIS MAGNA 2-4 ROOM

VII SESSION

IRON DEFICIENCY, ANEMIA AND CARDIORENAL SYNDROME

Chairmen: *M. Fusaro* (Padua), *R. Rivera* (Desio)

17.30 Iron deficiency, anemia and heart failure: an up to date
P. Terrosu (Sassari)

17.50 Multidisciplinary Round Table
Internal Medicine point of view
D. Girelli (Verona)

Nephrologist's point of view
R. Minutolo (Naples)

Cardiologist's point of view
M. Senni (Bergamo)

18.50 Discussion

LEPTIS MAGNA 1 ROOM

VII SESSION

DIABETIC PATIENT WITH METABOLIC SYNDROME: REAL WORLD EVIDENCES

Chairmen: *R. Addesse* (Tivoli), *V. Toscano* (Rome)

17.30 Hypoglycemic, but non-insulinemic therapy, in CKD patients:
how collect safety and efficacy in every CKD stages
S. Settembrini (Naples)

- 17.50** New therapies for dyslipidemia management in cardiorenal patients: the role of fixed pharmacological association
TBA
- 18.10** Omega-3 fatty acids and cardiovascular damage's prevention in CKD patients
A. De Pascalis (Lecce)
- 18.30** Statin therapy in dialysis patients: top or flop?
S. Andrucci (Lecco)
- 18.50** Discussion

TARRAGONA ROOM

VII SESSION

CARDIORENAL INVOLVEMENT IN SYSTEMIC VASCULITIS AND RARE DISEASES

Chairmen: *V. Montinaro* (Tricase), *A. Pani* (Cagliari)

- 17.30** Therapeutic perspectives in systemic vasculitis
S. Sciascia (Turin)
Discussant: *A. Mitrotti* (Bari)
- 17.50** Pathogenic classification of MGRS
A. Angioi (Cagliari)
Discussant: *G. Piscopo* (Bari)
- 18.10** Modulation of complement activation in atypical hemolytic uremic syndrome
G. Castellano (Bari)
Discussant: *A. Atzeni* (Cagliari)

18.30 Immunopathogenesis of idiopathic membranous nephropathy
M. Fiorentino (Bari)
Discussant: *D. Santoro* (Messina)

18.50 Discussion

19.00 **Closing**



DAY THREE - Thursday March 14th 2019

WORLD KIDNEY DAY

LEPTIS MAGNA 2-4 ROOM

VIII SESSION

FAST AND FURIOUS 1

CARDIORENAL ARENA ON CKD-MBD

Chairman: *F. Locatelli* (Lecco)

8.30 Burning questions 1

The role of calcimimetic in CKD

D. Russo (Naples)

Cinacalcet or etelcalcetide? To whom?

A. Bellasi (Bergamo)

Surgical parathyroidectomy?

S. Mazzaferro (Rome)

First round: wrap-up and take home messages

9.00 Burning questions 2

Biomarkers: PTH and alkaline phosphatase

M.C. Mereu (Cagliari)

The role of bone biopsy

M. Fusaro (Padua)

Vascular calcification: does it matter?

P. Raggi (Edmonton)

Second round: wrap-up and take home messages

9.30 Burning questions 3

Bone fractures in CKD patients

M. Di Luca (Pesaro)

Active or native Vitamin D?

M. Pasquali (Rome)

New calcium free phosphate binders

M. Cozzolino (Milan)

Third round: wrap-up and take home messages

10.00 Hypoparathyroidism and CKD

A. Sandonati (Rome)

10.15 PLENARY LECTURE

*Erythropoietin, chronic kidney disease and cardiovascular outcomes:
a 30 years history*

R. Rivera (Desio)

Introducing: *A. De Pascalis* (Lecce)

LEPTIS MAGNA 1 ROOM

VIII SESSION

DIABETIC NEPHROPATHY 1

Chairmen: *A. Selvi* (Perugia), *V. Toscano* (Rome)

8.30 Novel association therapies for every step of treatment

R. Buzzetti (Rome)

9.00 SGLT-2 inhibitors and cardiovascular outcomes: lessons from CVOTs and RWE studies

G. Pugliese (Rome)

9.30 GLP-1 agonists' impact on cardiovascular mortality and morbidity
S. Settembrini (Naples)

10.00 PLENARY LECTURE

New perspectives in the treatment of diabetic nephropathy

R. Minutolo (Naples)

Introducing: *G. La Manna* (Bologna)

TARRAGONA ROOM

VIII SESSION

CLINICAL NUTRITION IN NEPHROLOGY: ISSUES OF DAILY CLINICAL PRACTICE IN CKD

Relevant nutritional topics for CKD patients, caregivers and clinicians in Nephrology

Chairmen: *V. Bellizzi* (Salerno), *G. Brunori* (Trento)

8.30 Introduction
G. Brunori (Trento)

8.35 What the CKD patients ask to social media on nutritional treatment?
G. Quintaliani (Perugia)

8.50 Priorities on nutritional treatment in CKD according to stakeholders
V. Bellizzi (Salerno)

9.05 Discussion

Practical renal nutrition issues in the real life

Chairmen: *V. Bellizzi* (Salerno), *B. Di Iorio* (Avellino)

9.15 Low-proteins/high-carbohydrates or normal-proteins/low-carbohydrates diet in diabetic CKD patients?
D. Santoro (Messina)

- 9.30** Safety of very low-protein/vegetarian diets in CKD:
hyperkalemia
B. Di Iorio (Avellino)
- 9.45** Salt intake and autosomal dominant polycystic kidney disease
F. Scolari (Brescia)
- 10.00** Dietary modulation of Gut Microbioma in CKD
E. Fiaccadori (Parma)
- 10.15** Advice or device to improve adherence to nutritional treatment
in CKD?
C. D'Alessandro (Pisa)
- 10.30** Discussion

EXHIBIT HALL

- 10.45** Poster Session
Discussant: *F.R. Festuccia* (Rome), *V. Pistolesi* (Rome)

LEPTIS MAGNA 2-4 ROOM

IX SESSION

FAST AND FURIOUS 2

CARDIORENAL ARENA ON ATRIAL FIBRILLATION IN CKD

Chairmen: *F.R. Pugliese* (Rome), *F. Summaria* (Rome)

- 11.15** **Burning questions 1 - CKD and Heart Failure**

Fast: Which DOAC should be used?

L. Di Lullo (Colleferro)

Furious: Please, do not use DOACs

G. Pulignano (Rome)

Neither “Fast” or “Furious”: Vitamin K antagonists and CKD: angel or devil?

A. Bellasi (Bergamo)

First round: wrap-up and take home messages

11.45 Burning questions 2 - The Real World

Fast: DOACs and CKD: from clinical trials to real world data

M. Uguccioni (Rome)

Furious: Frail and older patients with CKD: which DOAC?

A. Ungar (Florence)

Neither “Fast” or “Furious”: Thromboembolic and hemorrhagic risk score calculators in CKD

M. Ravera (Genoa)

Second round: wrap-up and take home messages

12.15 Burning questions 3 - CKD and atrial fibrillation in Emergency Department

Fast: An highway to cardioversion

C. Lavalle (Rome)

Furious: Pulmonary embolism prevention

M.P. Ruggieri (Rome)

Neither “Fast” or “Furious”: Deep venous thrombosis management

L. Zuccaro (Rome)

Third round: wrap-up and take home messages

13.00 Anticoagulant therapy and cardiovascular calcifications progression

A. De Vriese (Bruges - Belgium)

LEPTIS MAGNA 1 ROOM

IX SESSION

DIABETIC NEPHROPATHY 2

Chairmen: *G. Del Rosso* (Teramo), *E. Paoletti* (Genoa)

- 11.15** Diabetic nephropathy and cardiovascular implications
M. Ravera (Genoa)
- 11.30** DPP-IV efficacy and safety in CKD patients:
new real world data
N. Napoli (Terracina)
- 11.45** Diabetic disease's management in dialysis patients
O. Disoteo (Milan)

X SESSION

NEW TECHNOLOGIES IN CARDIONEPHROLOGY

Chairmen: *N. Rifichi* (Latina), *F. Tulli* (Palestrina)

- 12.00** HFR and cardiovascular outcome
G. La Manna (Bologna)
- 12.15** Percutaneous coronary intervention in high-risk patients with
co-morbidities and multivessel coronary artery disease
V. Pasceri (Rome)
- 12.30** HFR and hepcidin removal
G. Donati (Bologna)
- 12.45** Progress in cardiac pacing: which role for the leadless devices?
N. Di Belardino (Anzio)
- 13.00** Discussion

TARRAGONA ROOM

IX SESSION

APHERESIS IN CARDIORENAL PATIENTS

Chairman: *A. Santoro* (Bologna)

- 11.15** Lipoprotein (a) – risk marker and therapeutic target
R. Klingel (Frankfurt - Germany)
- 11.30** Rheopheresis and microvascular complications in cardiorenal patients
A. Ramunni (Bari)
- 11.45** Discussion

X SESSION

INTERACTIVE TRAINING SESSION FOR DIETICIANS IN CARDIO-NEPHRO-DIABETOLOGY

LEPTIS MAGNA 2-4 ROOM

XI SESSION

CARDIOVASCULAR INVOLVEMENT IN PATIENTS WITH HEMODIALYSIS VASCULAR ACCESS

Chairmen: *M. Gallieni* (Milan), *M. Tozzi* (Varese)

- 13.20** The impact of haemodialysis arteriovenous fistula on haemodynamic parameters of the cardiovascular system
J. Malik (Ljubjana - Slovenia)
- 13.40** Cardiovascular disease and HD: cvc trigger or destiny
C. Lomonte (Aquaviva delle Fonti)
- 13.55** Cardiac implantable electronic device and vascular access: Strategies to overcome problems
F. Caravati (Varese)

- 14.10** High-range FAV and theft syndromes: possible strategies
N. Pirozzi (Rome)
- 14.25** Graft for low flow VA: an option for patients with heart failure
M. Tozzi (Varese)
- 14.40** Radiological intervention in high flow access
P. Quaretti (Pavia)
- 14.55** Discussion

LEPTIS MAGNA 1 ROOM

XI SESSION

NURSES AND CLINICIANS INTERACTIVE SESSION ON CARDIONEPHROLOGY

Chairmen: *R. Mari* (Colleferro), *U. Tulli* (Tivoli)

CRRT and nurses. Learning to the job-Downtime
P. Martucci (Rome)

Central Venous Catheters: guidelines, bundle and best practice
A. Fontana (Tivoli)

CKD patients' fluids and electrolytes management in Intensive
Care Units
S. Accardo (Rome)

CRRT and available anticoagulation strategies: which is the
best one?
TBA

15.00 CLOSING REMARKS FAREWELL PARTY

SCIENTIFIC INFORMATION

EDUCATIONAL COURSES

Educational Courses will take place on Tuesday, March 12th from 9.00 to 13.00. Participation at the courses is free, but a pre-registration is required.

E-POSTER

During the Congress, a Poster Session will take place on Thursday, March 14th from 10.45 until 11.45

Scientific works must be sent by January 15th, 2019 through the website <https://fenicia-events.eu/cardionefro/call-for-abstract/>

All the abstracts must be received exclusively in electronic and in English, completing the special form. The first Author will be considered as the one who will make the presentation and must be regularly registered at the Congress; Authors under 35 will be entitled to free admission to the Congress.

PUBLICATION OF ABSTRACT

All the abstracts received will be published on the website www.feniciaevents.eu/cardionefro, and three best abstracts will be published in the Cardionefro Magazine

CME

For the Italian Participants: Cardionephrology 2019 will participate at the Continuing Medical Education

SCIENTIFIC TECHNICAL EXHIBITION

During the Congress an exhibition will be set up for biomedical, pharmaceutical and scientific publishing industry

- Tuesday, March 12th 9.00-20.00
- Wednesday, March 13th 8.30-19.00
- Thursday, March 14th 8.30-14.30

ORGANIZING SECRETARY ON SITE

Organizing Secretariat in the Congress Venue will observe the following timetable:

- Monday, March 11th (only for Delegations and Companies) 9.00-19.00
- Tuesday March 12th 8.00-20.00
- Wednesday March 13th 8.00-19.30
- Thursday March 14th 8.00-15.00

GENERAL INFORMATION

VENUE

ERGIFE PALACE HOTEL Largo Lorenzo Mossa

For information and hotel reservations please contact the Organizing Secretariat:

FENICIA EVENTS & COMMUNICATION

Phone: +39 06 87671411 - Fax: +39 06 62278787

Cardionefro2019@fenicia-events.eu;

<https://fenicia-events.eu/cardionefro>

REGISTRATION

Congress website <https://feniciaevents.eu/cardionefro/iscrizioni/>

REGISTRATION FEES (rates include VAT 22%)

	<i>By December 31st 2018</i>	<i>After that date</i>
Doctors	€ 122,00	€ 183,00
Nurses/Dietitians	€ 61,00	€ 91,50
* Postgraduate	€ 61,00	€ 91,50
* Students	free of charge	free of charge

** Each student and trainees must submit a copy of the certificate of registration at Specialities School.*

Registration fee includes: participation in all scientific sessions, coffee breaks and light lunch, farewell party, certificate of attendance, badge and congress bag.

BADGE AND CERTIFICATE OF PARTICIPATION

Badge and the certificate of attendance can be printed by all the participants at the desks prepared using their QRCode received by e-mail when registering for the event.

CANCELLATIONS AND REFUNDS

Any refund will be recognized

OFFICIAL LANGUAGES OF THE CONGRESS

English and Italian.

Translation tool will be available in the following rooms:

Leptis Magna 2-4

Leptis Magna 1

Tarragona

HOW TO REACH THE VENUE

Hotel Ergife Palace is located about 200 meters from Via Aurelia, just 4 km from Grande Raccordo Anulare and 26 km from Fiumicino airport. The major points of cultural and commercial importance of the city are easily reachable with the bus lines and the underground that allow the connection.

PUBLIC TRANSPORTATION Hotel is easily reachable by public transport, especially for those arriving from Termini station or from the center of Rome using the underground line A and getting off at Cornelia, then about 1.200 meters, about 15 minutes to walk or bus 246. 2 stops (get off at the Pio IX clinic) leaving from Piazza Irnerio. **BY TRAIN** From Termini Station take the underground line A towards Battistini and get off at Cornelia. Then take the line 246 towards Malagrotta and get off after 3 stops.

BY PLANE From Fiumicino airport: Leonardo Da Vinci airport is about 25 km from the hotel. A direct train (Leonardo Express) leaves the airport every 30 minutes and connects Fiumicino to Roma Termini. Once in Termini take the metro line A direction Battistini, stop Cornelia. From Cornelia take bus 246 for three stops. The hotel is just a few steps from the stop.

From Ciampino airport: Ciampino airport is about 30 km from Ergife Palace Hotel. With Terravision bus you can easily reach the Termini station. From Termini it is possible to reach the hotel by taxi or by taking the metro line A direction Battistini. From Ciampino to the hotel by taxi the ride lasts about 40 minutes and costs about 50.00. You can also reach Termini by bus CO.TRA.L. Once to Termini take the metro line A direction Battistini, get off Cornelia. From Cornelia take the bus 246 for three stops. The hotel is a few steps from the bus stop.

BY CAR At the exit of the motorway take the Grande Raccordo Anulare towards Fiumicino exit n.1. Direction Aurelia-Città del Vaticano. After about

3 Km at the fourth traffic light turn right into Via Lombardi.. The hotel is at the bottom of the Street.

PARKING

The Hotel has a parking for 800 paid parking spaces (€ 15,00 per day).

ORGANIZING SECRETARIAT



Fenicia Events & Communication

Via Tor de' Conti, 22 - 00184 Roma

Tel. +39 06.87671411 - Fax +39 06.62278787

WhatsApp +39 342.8211587 - info@fenicia-events.eu